Siegfried Holding AG Acquires Noramco, Extractas Biosciences, and Purisys from SK Capital Partners
January 27, 2026
Siegfried Holding AG has acquired Noramco, Extractas Biosciences, and Purisys (the Noramco Group) from affiliates advised by SK Capital Partners. The deal added small-molecule API/CDMO drug substance capabilities to Siegfried, while SK Capital retained Halo Pharmaceuticals as a standalone finished-dose-form CDMO.
- Buyers
- Siegfried Holding AG
- Targets
- Noramco, Extractas Biosciences, Purisys, Noramco Group
- Sellers
- Affiliates of funds advised by SK Capital Partners, LP (SK Capital Partners)
- Industry
- Healthcare Services
- Location
- Delaware, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.